Header_Background_v2.jpg

NASH Connect

By 2025, NASH is expected to become the leading indication of liver transplantation in the United States.

This CME-accredited event will be presented live and virtually and will examine current practice guidelines regarding the screening, diagnosis, staging, treatment, and management of these patients as well as review potential next-generation therapies.

A multidisciplinary team will lead this discussion and will include hepatologists, gastroenterologists, endocrinologists, diabetologists, obesity specialists, cardiologists, and primary care physicians.